Abiraterone acetate is named as an intervention in 30 current clinical trials in our USA, UK, China, Ireland and India registers. 10 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (6). The most-studied condition is Prostatic Neoplasms.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
15 single-substance products containing Abiraterone acetate on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Prostatic Neoplasms | 6 |
| Metastatic Prostate Cancer | 4 |
| Metastatic Castration-resistant Prostate Cancer | 4 |
| Prostate Cancer | 3 |
| Metastatic Castration-Resistant Prostate Cancer | 2 |
| Advanced Prostate Cancer | 2 |
| Prostate Cancer Metastatic | 1 |
| Metastatic Castration-resistant Prostate Cancer (mCRPC) | 1 |
| Metastatic Hormone Sensitive Prostate Cancer | 1 |
| Prostatic Neoplasms, Castration-Resistant | 1 |
| Castration-Resistant Prostatic Cancer | 1 |
| Hormone-Sensitive Prostate Cancer | 1 |
| Prostate Adenocarcinoma | 1 |
| Metastatic Castration-Sensitive Prostate Cancer | 1 |
| Metastatic Castration-resistant Prostate Neoplasms | 1 |
| Metastatic Hormone-sensitive Prostate Cancer | 1 |
| Metastatic Cancer | 1 |
| Neoplasm, Prostate | 1 |
| Castrate-sensitive | 1 |
| Castrate-sensitive Prostate Cancer | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Hormone-Sensitive Prostate Cancer | 1 |
| Neoadjuvant Therapy | 1 |
| High Risk Prostate Cancer | 1 |
| Locally Advanced Prostate Cancer | 1 |
| Intense Endocrine Therapy | 1 |
| Abiraterone Acetate | 1 |
| MCRPC (metastatic Castration-resistant Prostate Cancer) | 1 |
| Diagnosed With Metastatic Prostate Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 6 |
| Janssen Research & Development, LLC | 6 |
| Merck Sharp & Dohme LLC | 2 |
| Astellas Pharma Global Development, Inc. | 2 |
| Aragon Pharmaceuticals, Inc. | 2 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2 |
| UNICANCER | 1 |
| Amgen | 1 |
| Exelixis | 1 |
| Sun Pharmaceutical Industries Limited | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Eli Lilly and Company | 1 |
| Bayer | 1 |
| Ding-Wei Ye | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 |
+ 1 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 22 | 7 |
| Clinical trials in UK | 16 | 4 |
| Clinical trials in China | 16 | 6 |
| Clinical trials in Ireland | 3 | 2 |
| Clinical trials in India | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
30 current trials in our USA, UK, China, Ireland and India registers name Abiraterone acetate as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 10 of the 30 trials are recruiting: 7 with sites in USA, 4 with sites in UK, 6 with sites in China and 2 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (6), Janssen Research & Development, LLC (6), Merck Sharp & Dohme LLC (2) and Astellas Pharma Global Development, Inc (2), among 16 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 15 single-substance products containing Abiraterone acetate, for example Abiraterone Aristo 500 mg film-coated tablets (Aristo Pharma GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 3 entries for Abiraterone acetate: 3 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Abiraterone acetate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Abiraterone acetate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Abiraterone acetate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.